Ryan Hankins, MD
Urology · Washington, DCNPI 1164712469
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 81.9% of it on its own, with 27 other manufacturers making up the rest. Among urology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $203.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$23K
- Angiodynamics, Inc.$2K
- Neotract Inc.$737
- Urogen Pharma, Inc.$298
- Procept Biorobotics Corporation$274
- Abbott$255
- plus $2K from 22 others
What the payments were for
- Consulting fees$13,55048%
- Speaking & faculty fees$6,50523%
- Travel & lodging$3,59013%
- Food & beverage$4,86117%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 57 | $23,361 |
| Angiodynamics, Inc. | 7 | $1,799 |
| Neotract Inc. | 8 | $737 |
| Urogen Pharma, Inc. | 5 | $298 |
| Procept Biorobotics Corporation | 5 | $274 |
| Abbott | 2 | $255 |
| Integra Lifesciences Corporation | 4 | $244 |
| Corcept Therapeutics | 8 | $209 |
| Antares Pharma, Inc. | 6 | $206 |
| Sumitomo Pharma America, Inc. | 8 | $191 |
| Endo Pharmaceuticals Inc. | 3 | $162 |
| Baxter Healthcare | 1 | $122 |
| Progenics Pharmaceuticals, Inc. | 1 | $96 |
| Tolmar, Inc. | 3 | $92 |
| Urovant Sciences Inc | 4 | $83 |
| AbbVie | 3 | $62 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $47 |
| Laborie Medical Technologies Corp. | 2 | $45 |
| Astellas Pharma US Inc | 1 | $41 |
| Axonics, Inc. | 2 | $35 |
| Intuitive Surgical | 1 | $28 |
| Johnson & Johnson | 1 | $26 |
| Endo USA, Inc. | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $21 |
| Calyxo, Inc. | 1 | $19 |
| Valencia Technologies Corporation | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SpaceOAR System$18,187
- SpaceOAR VUE System - 10mL$1,844
- Nanoknife$1,771
- UroLift$648
- Perclose ProGlide suture mediated closure system$255
- AquaBeam Robotic System$165
- JELMYTO$134
- AMS$132
- BILAYER WOUND MATRIX (BWM)$128
- INTEGRA WOUND MATRIX (IWM)$128
- AMNIOEXCEL$128
- IDRT$128
- FLOWABLE$128
- AMS 700$123
- TISSEEL$122
- XIAFLEX$121
- GENERAL ERECTILE DYSFUNCTION$114
- GENERAL - THERAPIES$110
How this compares
$28,508 in reported general payments places this provider in the 90th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 221 | $252,739 |
| ThiolaTiopronin | 11 | $77,620 |
| GemtesaVibegron | 39 | $38,494 |
| Trospium Chloride ErTrospium Chloride | 76 | $22,799 |
| Potassium Citrate ErPotassium Citrate | 98 | $12,793 |
| Mirabegron ErMirabegron | 15 | $11,744 |
| Tamsulosin Hcl | 574 | $11,228 |
| Testosterone | 30 | $9,002 |
| Solifenacin Succinate | 91 | $6,084 |
| Finasteride | 259 | $5,190 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 161 | $4,593 |
| Tolterodine Tartrate ErTolterodine Tartrate | 23 | $3,564 |
| Trospium Chloride | 36 | $2,821 |
| Estradiol | 15 | $2,095 |
| Methenamine Hippurate | 23 | $1,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $41 | $252,739221 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $191 | $38,49439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 47 urology providers in District of Columbia.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Patrick MufarrijWashington$31K
- Adam MetwalliWashington$27K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Jason EngelWashington$12K
- Keith KowalczykWashington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.